64 results
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure
8-K
EX-1.1
SEEL
Seelos Therapeutics Inc
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post
424B5
SEEL
Seelos Therapeutics Inc
30 Nov 23
Prospectus supplement for primary offering
4:58pm
requirements, or shut down our manufacturing operations; or
seize or detain products or require a product recall.
The FDA, the EMA and comparable
424B5
SEEL
Seelos Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:06pm
requirements, or shut down our manufacturing operations; or
seize or detain products or require a product recall.
The FDA, the EMA and comparable
8-K
EX-10.1
0ihfhwfg
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
424B5
tdjlz4xb
25 Sep 23
Prospectus supplement for primary offering
6:02am
424B5
546tkr0fjyls1zx
12 May 22
Prospectus supplement for primary offering
8:30am
8-K
EX-10.1
7d2285 tm
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
424B5
zduwcap
21 May 21
Prospectus supplement for primary offering
12:00am
424B5
i42wg
19 May 21
Prospectus supplement for primary offering
4:08pm